pyrimethamine has been researched along with Stillbirth in 8 studies
Maloprim: contains above 2 cpds
Stillbirth: The event that a FETUS is born dead or stillborn.
Excerpt | Relevance | Reference |
---|---|---|
"Adequate prevention regimen with monthly sulfadoxine-pyrimethamine given to all pregnant women has been proved to reduce the risk of LBW in malaria endemic areas." | 9.69 | Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial. ( Derra, K; Donnen, P; Dramaix, M; Kaboré, B; Lingani, M; Robert, A; Rouamba, T; Samadoulougou, S; Sanou, M; Somé, G; Sorgho, H; Tahita, MC; Tinto, H; Valéa, I; Zango, SH, 2023) |
"In the context of the increasing resistance to sulfadoxine-pyrimethamine (SP), we evaluated the efficacy of mefloquine (MQ) for intermittent preventive treatment during pregnancy (IPTp)." | 9.14 | Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. ( Ayemonna, P; Bottero, J; Briand, V; Cordel, H; Cot, M; Fayomi, B; Fievet, N; Guerra, J; Kossou, H; Masse, V; Massougbodji, A; Noël, H, 2009) |
"Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity." | 8.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
"Adequate prevention regimen with monthly sulfadoxine-pyrimethamine given to all pregnant women has been proved to reduce the risk of LBW in malaria endemic areas." | 5.69 | Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial. ( Derra, K; Donnen, P; Dramaix, M; Kaboré, B; Lingani, M; Robert, A; Rouamba, T; Samadoulougou, S; Sanou, M; Somé, G; Sorgho, H; Tahita, MC; Tinto, H; Valéa, I; Zango, SH, 2023) |
"Emerging malaria parasite sulfadoxine-pyrimethamine (SP) resistance has prompted assessment of alternatives for intermittent preventive treatment in pregnancy (IPTp)." | 5.30 | A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women. ( Benjamin, JM; Davis, TME; Kasian, B; Kong, C; Laman, M; Moore, BR; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, S; Tobe, R; Yadi, G, 2019) |
"In the context of the increasing resistance to sulfadoxine-pyrimethamine (SP), we evaluated the efficacy of mefloquine (MQ) for intermittent preventive treatment during pregnancy (IPTp)." | 5.14 | Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. ( Ayemonna, P; Bottero, J; Briand, V; Cordel, H; Cot, M; Fayomi, B; Fievet, N; Guerra, J; Kossou, H; Masse, V; Massougbodji, A; Noël, H, 2009) |
"Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity." | 4.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
"Intermittent preventive treatment (IPTp) for pregnant women with sulfadoxine-pyrimethamine (SP) is widely implemented for the prevention of malaria in pregnancy and adverse birth outcomes." | 4.31 | Impact of Intermittent Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenyan Coast. ( Amadi, D; Bejon, P; Berkley, JA; Kamau, A; Musau, M; Mwakio, S; Nyaguara, A; Seale, AC; Snow, RW, 2023) |
"Effective intermittent preventive treatment in pregnancy (IPTp) diminishes placental malaria (PM) and its subsequent malaria-associated morbidity." | 2.50 | Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. ( Abellana, R; Cot, M; Moya-Alvarez, V, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 3 (37.50) | 2.80 |
Authors | Studies |
---|---|
Kamau, A | 1 |
Musau, M | 1 |
Mwakio, S | 1 |
Amadi, D | 1 |
Nyaguara, A | 1 |
Bejon, P | 1 |
Seale, AC | 1 |
Berkley, JA | 1 |
Snow, RW | 1 |
Lingani, M | 1 |
Zango, SH | 1 |
Valéa, I | 1 |
Samadoulougou, S | 1 |
Somé, G | 1 |
Sanou, M | 1 |
Kaboré, B | 1 |
Rouamba, T | 1 |
Sorgho, H | 1 |
Tahita, MC | 1 |
Derra, K | 1 |
Dramaix, M | 1 |
Tinto, H | 1 |
Donnen, P | 1 |
Robert, A | 1 |
Moore, BR | 1 |
Benjamin, JM | 1 |
Tobe, R | 1 |
Ome-Kaius, M | 1 |
Yadi, G | 1 |
Kasian, B | 1 |
Kong, C | 1 |
Robinson, LJ | 1 |
Laman, M | 1 |
Mueller, I | 1 |
Rogerson, S | 1 |
Davis, TME | 1 |
Ategeka, J | 1 |
Kakuru, A | 1 |
Kajubi, R | 1 |
Wasswa, R | 1 |
Ochokoru, H | 1 |
Arinaitwe, E | 1 |
Yeka, A | 1 |
Jagannathan, P | 1 |
Kamya, MR | 1 |
Muehlenbachs, A | 1 |
Chico, RM | 1 |
Dorsey, G | 1 |
González, R | 1 |
Pons-Duran, C | 1 |
Piqueras, M | 1 |
Aponte, JJ | 1 |
Ter Kuile, FO | 1 |
Menéndez, C | 1 |
Moya-Alvarez, V | 1 |
Abellana, R | 1 |
Cot, M | 3 |
Briand, V | 2 |
Escolano, S | 1 |
Journot, V | 1 |
Massougbodji, A | 2 |
Tubert-Bitter, P | 1 |
Bottero, J | 1 |
Noël, H | 1 |
Masse, V | 1 |
Cordel, H | 1 |
Guerra, J | 1 |
Kossou, H | 1 |
Fayomi, B | 1 |
Ayemonna, P | 1 |
Fievet, N | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants[NCT02793622] | Phase 3 | 782 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine[NCT00274235] | Phase 3 | 1,600 participants (Anticipated) | Interventional | 2005-07-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria. (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 44 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 24 |
Admission to the pediatric ward for any cause (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 19 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
episodes per person year (NCT02793622)
Timeframe: Time at risk will begin at birth and end when study participants reaches 12 months of age or early study termination
Intervention | episodes per person year (Number) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 1.98 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1.71 |
Any deaths occurring after birth (NCT02793622)
Timeframe: Birth up to 12 months of age
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 9 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 |
Gestational age in weeks determined by ultrasound dating (gold standard) and by the metabolic profiling outcome from biological specimens including placental tissue and placental blood. (NCT02793622)
Timeframe: At the time of delivery
Intervention | weeks (Mean) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 39.4 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 39.6 |
Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (< 2500 gm); 2) Preterm delivery (< 37 weeks gestational age); 3) Small for gestational age (< 10th percentile relative to an external growth reference) (NCT02793622)
Timeframe: Delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 60 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 54 |
All grade 3 and 4 adverse events (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 54 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 43 |
"Defined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age. Number of cases per person year (PPY).~This is a prevalence measure but are repeated measures during infancy. In other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age)." (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
Intervention | routine hemoglobin measurement (Count of Units) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 222 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 216 |
hemoglobin < 11 g/dL (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
Intervention | blood smears (Count of Units) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 344 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 357 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
Intervention | blood smears (Count of Units) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 519 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 9 |
Maternal blood positive for malaria parasites by microscopy. (NCT02793622)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1 |
Any evidence of placental infection (parasites or pigment). Number of participants with placental tissue positive for malaria parasites or pigment. (NCT02793622)
Timeframe: Delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 197 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 94 |
Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy (NCT02793622)
Timeframe: Delivery
Intervention | Participants (Count of Participants) | |
---|---|---|
LAMP | Microscopy | |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 | 1 |
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 71 | 29 |
2 reviews available for pyrimethamine and Stillbirth
Article | Year |
---|---|
Mefloquine for preventing malaria in pregnant women.
Topics: Anemia; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; HIV Seronegativity; Hum | 2018 |
Pregnancy-associated malaria and malaria in infants: an old problem with present consequences.
Topics: Adult; Africa South of the Sahara; Antimalarials; Comorbidity; Complement Activation; Developmental | 2014 |
4 trials available for pyrimethamine and Stillbirth
Article | Year |
---|---|
Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial.
Topics: Abortion, Spontaneous; Antimalarials; Azithromycin; Birth Weight; Burkina Faso; Drug Combinations; F | 2023 |
A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
Topics: Adult; Antimalarials; Asymptomatic Diseases; Azithromycin; Chemoprevention; Drug Combinations; Eryth | 2019 |
Mefloquine Versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment in Pregnancy: A Joint Analysis on Efficacy and Tolerability.
Topics: Anemia; Antimalarials; Benin; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Malaria; | 2015 |
Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antimalarials; Drug Combinations; Female; | 2009 |
2 other studies available for pyrimethamine and Stillbirth
Article | Year |
---|---|
Impact of Intermittent Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenyan Coast.
Topics: Antimalarials; Drug Combinations; Female; Humans; Kenya; Malaria; Pregnancy; Pregnancy Complications | 2023 |
Relationships Between Measures of Malaria at Delivery and Adverse Birth Outcomes in a High-Transmission Area of Uganda.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Infan | 2020 |